# Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

> **NCT03026348** · PHASE2 · COMPLETED · sponsor: **Novavax** · enrollment: 300 (actual)

## Conditions studied

- Respiratory Syncytial Viruses

## Interventions

- **BIOLOGICAL:** RSV F Vaccine with Aluminum Phosphate Adjuvant
- **BIOLOGICAL:** RSV F Vaccine
- **BIOLOGICAL:** Matrix-M1 Adjuvant
- **OTHER:** Phosphate Buffer

## Key facts

- **NCT ID:** NCT03026348
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2017-04
- **Final completion:** 2018-05-18
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2021-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03026348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03026348, "Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03026348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*